Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554042 | 0.86 | L3MBTL1 (0.46) | L3MBTL1AKR1C3AKR1C2CYP11B1CYP11B2 | |
| SCHEMBL19013605 | 0.78 | L3MBTL1 (0.60) | NR1H2L3MBTL1ATRATRIPAKR1C3 | |
| SCHEMBL29631943 | 0.78 | L3MBTL1 (0.60) | NR1H2L3MBTL1ATRATRIPAKR1C3 | |
| SCHEMBL30077038 | 0.76 | NR1H2 (0.49) | NR1H2ATRATRIPAKR1C3AKR1C2 | |
| SCHEMBL3301415 | 0.76 | NR1H2 (0.53) | NR1H2ATRATRIPAPP | |
| SCHEMBL424044 | 0.76 | MAPK1 (0.42) | L3MBTL1HPGDS | |
| SCHEMBL2934932 | 0.75 | NR1H2 (0.44) | NR1H2TRPV3 | |
| SCHEMBL12100103 | 0.74 | NR1H2 (0.43) | NR1H2L3MBTL1ATRATRIPAKR1C3 | |
| SCHEMBL12685165 | 0.73 | AKR1C3 (0.57) | NR1H2L3MBTL1ATRATRIPAKR1C3 | |
| SCHEMBL18335203 | 0.73 | NR1H2 (0.40) | NR1H2L3MBTL1ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | APP, IDO2, IDO1 | NR1H2 1715/4885L3MBTL1 4571/4885ATR 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.